Neutrophil activator of matrix metalloproteinase-2 (NAM)

被引:0
|
作者
Ellen E. Rollo
Michelle Hymowitz
Cathleen E. Schmidt
Steve Montana
Hussein Foda
Stanley Zucker
机构
[1] Veterans Affairs Medical Center,Departments of Research and Medicine
[2] State University of New York at Stony Brook,School of Medicine
来源
关键词
Extracellular matrix; Matrix metalloproteinase (MMP); Metastasis; MMP activation; Neutrophil; Cancer;
D O I
暂无
中图分类号
学科分类号
摘要
We have isolated a novel soluble factor(s), neutrophil activator of matrix metalloproteinases (NAM), secreted by unstimulated normal human peripheral blood neutrophils that causes the activation of cell secreted promatrix metalloproteinase-2 (proMMP-2). Partially purified preparations of NAM have been isolated from the conditioned media of neutrophils employing gelatin-Sepharose chromatography and differential membrane filter centrifugation. NAM activity, as assessed by exposing primary human umbilical vein endothelial cells (HUVEC) or HT1080 cells to NAM followed by gelatin zymography, was seen within one hour. Tissue inhibitor of metalloproteinase-2 (TIMP-2) and hydroxamic acid derived inhibitors of MMPs (CT1746 and BB94) abrogated the activation of proMMP-2 by NAM, while inhibitors of serine and cysteine proteases showed no effect. NAM also produced an increase in TIMP-2 binding to HUVEC and HT1080 cell surfaces that was inhibited by TIMP-2, CT1746, and BB94. Time-dependent increases in MT1-MMP protein and mRNA were seen following the addition of NAM to cells. These data support a role for NAM in cancer dissemination.
引用
收藏
页码:259 / 268
页数:9
相关论文
共 50 条
  • [21] An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy
    Han, Sang Youb
    Jee, Yi Hwa
    Han, Kum Hyun
    Kang, Young Sun
    Kim, Hyoung Kyu
    Han, Jee Young
    Kim, Young Sik
    Cha, Dae Ryong
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (09) : 2406 - 2416
  • [22] Evaluation of matrix metalloproteinase-2 in lung cancer
    Ali-Labib, Randa
    Louka, Manal Louis
    Galal, Iman Hassan El-Sayed
    Tarek, Marwa
    PROTEOMICS CLINICAL APPLICATIONS, 2014, 8 (3-4) : 251 - 257
  • [23] Arylsulfonamides and selectivity of matrix metalloproteinase-2: An overview
    Adhikari, Nilanjan
    Mukherjee, Avinaba
    Saha, Achintya
    Jha, Tarun
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 129 : 72 - 109
  • [24] Matrix metalloproteinase-2 promoter variability in psoriasis
    Vladimir Vasku
    Julie Bienertova Vasku
    Veronika Slonková
    Kateřina Kaňková
    Anna Vasku
    Archives of Dermatological Research, 2009, 301 : 467 - 473
  • [25] Matrix metalloproteinase-2 and mesangiolysis in diabetic nephropathy
    Kanauchi, M
    Nishioka, H
    Kawano, T
    Uyama, H
    Shiiki, H
    Dohi, K
    NEPHRON, 1999, 83 (02): : 174 - 175
  • [26] Matrix metalloproteinase-2: Not (just) a "hero" of the past
    Henriet, Patrick
    Emonard, Herve
    BIOCHIMIE, 2019, 166 : 223 - 232
  • [27] Inhibition of matrix metalloproteinase-2 by PARP inhibitors
    Nicolescu, Adrian C.
    Holt, Andrew
    Kandasamy, Arulmozhi D.
    Pacher, Pal
    Schulz, Richard
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 387 (04) : 646 - 650
  • [28] Ceruloplasmin binds and inactivates matrix metalloproteinase-2
    Thompson, Michael W.
    FASEB JOURNAL, 2012, 26
  • [29] Development of Matrix Metalloproteinase-2 Inhibitors for Cardioprotection
    Bencsik, Peter
    Kupai, Krisztina
    Goerbe, Aniko
    Kenyeres, Eva
    Varga, Zoltan V.
    Paloczi, Janos
    Gaspar, Renata
    Kovacs, Laszlo
    Weber, Lutz
    Takacs, Ferenc
    Hajdu, Istvan
    Fabo, Gabriella
    Cseh, Sandor
    Barna, Laszlo
    Csont, Tamas
    Csonka, Csaba
    Dorman, Gyoergy
    Ferdinandy, Peter
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [30] Control of matrix metalloproteinase-2 activity by phosphorylation
    Sariahmetoglu, M
    Leon, H
    Sawicka, J
    Sawicki, G
    Schulz, R
    FASEB JOURNAL, 2004, 18 (05): : A1115 - A1115